Kleo Pharmaceuticals

Developing a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and infectious diseases

placeNew Haven, Connecticut, United States calendar_todayFounded 2015 groups20 employees language kleopharmaceuticals.com

Registered entities

Innovation

6 patent families (4 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 271 times.

YearFilings
20181
20193
20203
20214
20224
20233
20243
20254
20262

Investor mix

4 investors on record; lead investors include PeptiDream, Biohaven Pharmaceutical.

Investor typeCountShare
Venture capital125%
Other / undisclosed375%
Coming soon